الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 83 |  |  |
| | | from | 83 | | |
Abstract
In the past, stimulation of follicular growth with pharmacological agents has been restricted mainly to women with oligomenorrhea or amenorhoea without ovarian failure. However these drugs have been used effectively to treat women with presumed luteal-phase defects as well as to induce the development of large numbers of follicles in order to facilitate recovery of multiple oocytes for various assisted reproductive technologies and even to provide empirical therapy for women with unexplained infertility.
Clomiphene citrate is the initial treatment for most anovulatory infertile women. Clomiphene citrate is easy to use and leads to ovulation in the vast majority of patients but pregnancy rates are disappointing (50 percent or less) lower than expected pregnancy rates with Clomiphene citrate have been attributed to its long half-life and peripheral antiestrogenic effects mainly on the endometrium and cervival mucous.
The next step is traditionally the administration of exogenous gonadotropin preparations. HCG is given for induction of ovulation because of its similarly to LH. The HCG is given by injection and can be used to stimulate ovulation and to support the subsequent luteal phase. The use of HCG for a long time can cause ovarian hyperstimulation syndrome.
Ovarian hyperstimulation syndrome (OHSS) is a clinical symptom complex associated with ovarian enlargement resulting from exogenous gonadotropin therapy. Then GnRHa is used to prevent ovarian hyperstimulation syndrome.
• The aim of this work was to compare the use of the HCG and the GnRHa in triggering ovulation process after clomiphene citrate treatment.
• This study was carried out on two groups, every group include 15 patients, thirty infertile female was selected randomly and were subjected the following: History